Banking - Yojana
Banking - Yojana
Banking - Yojana
- TAGS
- banking
- yojana
- yojana.gov.in
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Generated by PDFKit.NET Evaluation<br />
NEW HEALTH POUCY. ..<br />
(Contd. from page 27)<br />
potential ofIndiaas one of the eight<br />
global centres for plant diversity in<br />
. medicinal and aromatic plants. The<br />
. policy focuses on building up<br />
credibility for the alternative<br />
systems, by encouraging evidencebased<br />
research to determine their<br />
efficacy, safety and dosage and also<br />
encouraging certification and<br />
quality-marking of products to<br />
enable wider popular acceptance of<br />
these systems of medicine.<br />
The policy also envisages the<br />
consolidation of documentary<br />
knowledge contained in these<br />
systems to protect it against attack<br />
from foreign commercial entities by<br />
way of mala fide action under patent<br />
laws in other countries.<br />
As regards the impact of<br />
globalisation on the health sector,<br />
the policy admits that there are<br />
sqme apprehensions about the<br />
possible adverse impact of<br />
economic globalization on the<br />
health sector. Pharmaceutical drugs<br />
and other health services have<br />
always been available in the country<br />
at extremely inexpensive prices.<br />
India' has established a reputation<br />
around the globe for the innovative<br />
development of original process<br />
patents for the manufacture of widerange<br />
of drugs and vaccines within<br />
the ambit of the existing patent laws.<br />
With the adoption of Trade<br />
Related Inteliectual property Rights<br />
(TRIPS) ,and the subsequent<br />
alignment of domestic patent laws<br />
consistent with the commitments<br />
under TRIPS, there will be<br />
significant shift in the scope of the<br />
parameters regulating the<br />
manufacture of new drugs/vaccines.<br />
The policy observes that global<br />
experience has shown that the<br />
BY : NEETU'SINGH<br />
introduction of a TRIPS-consistent<br />
patent regime for drugs in a<br />
developing country results in an<br />
across-the board increase in the.cost<br />
of drugs and medical services. In this<br />
context, the policy merely states that<br />
it will address itself to the future<br />
imperatives of health security in the<br />
country, in the post-TRIPS era.<br />
However, it doesn't articulate any<br />
mechanism to regulate the<br />
exorbitant drug prices and the<br />
spiralling cost of health services to<br />
provide succour to a vast section of.<br />
the pOpulation in the low-income<br />
group when they may need these<br />
facilities. Already,' prices of various<br />
.essential drugs and formulations<br />
have gone up. This becomes the<br />
biggest challenge for the successful<br />
implementation of the new health<br />
policy which the health authorities<br />
jn the country srould be Pilying<br />
more<br />
years.<br />
attention to in the coming<br />
, 0<br />
Dour Drean1job is DepenDent on the k.nowleDge<br />
of ;90ur area of functional expertise anD it<br />
is with Direction tbat ;90U rea{{;9 clinch the<br />
Deal. 'W"ehelp ;90U anq.l;9ze ;9our eff~ctiveness<br />
to n1ake ;90U sta;9 current anDconten1pOrar;9<br />
, \ . ,<br />
54. Ralgher Pura. Arya Soma] Road. Karol Bagh. N.D.-5<br />
Ph: 011-5780662. 5861025.9810382305<br />
website: www.d.irectionlas,com. Email: mall@dlrectionlas.com;<br />
48 YOJANAJuly 2002<br />
Click here to unlock PDFKit.NET<br />
•